Quality of life

Olansky Dermatology & Aesthetics welcomes physician assistant, expands hours

Retrieved on: 
Tuesday, April 9, 2024
Psoriasis, Skin cancer, Patient, Mohs surgery, Aesthetics, Quality of life, Suite, Dermatology, Acne, Family

ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes physician assistant Kathryn “Katie” Shea to its Buckhead location.

Key Points: 
  • ATLANTA, April 09, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes physician assistant Kathryn “Katie” Shea to its Buckhead location.
  • This addition to the practice’s acclaimed staff allows Olansky Dermatology & Aesthetics the ability to offer new, expanded hours at its Buckhead location, a first for Atlanta area dermatology.
  • She has extensive experience in dermatology and urgent care medicine, and she is a member of the Georgia Association of Physician Assistants, American Academy of Physician Assistants, and Georgia Dermatology Physician Assistants.
  • “We strive to offer our patients the best providers possible,” says Dr. Jodi Ganz, physician partner at Olansky Dermatology & Aesthetics, “By growing our staff, it allows us to better meet patients where they are and provide additional hours for better flexibility.”
    Olansky Dermatology & Aesthetics is your dermatology solution.

Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey

Retrieved on: 
Tuesday, April 9, 2024
Adverse, Laxative, Gastrointestinal disease, Defecation, Patient, Human, American Journal, Weight loss, Constipation, News, Quality of life, Vibrant consonant, Hope, Invention, FDA

The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.

Key Points: 
  • The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.
  • Disrupting the U.S. $4.6 billion constipation treatment market, Vibrant Gastro’s first-in-class technology offers providers and patients with a new, non-pharmaceutical alternative to address this issue.
  • Patients track the progress of the treatment on their phone with an app to increase compliance, consistency and to monitor results.
  • A study presented at Digestive Disease Week in 2023 found significant symptomatic relief in patients and a substantially improved quality of life.

Food & Society at the Aspen Institute Releases the 2024 Food is Medicine Research Action Plan

Retrieved on: 
Tuesday, April 9, 2024
Emory University, Organization, Conference, Walmart, Policy, Associated, Health equity, Diabetes, Senior lecturer, Aspen, Research, Prescription, Doctor of Philosophy, Quality of life, White House conference, Society, Nutrition, University of Massachusetts, Aspen Institute, Physician, Meal, Dietary supplement

Washington, DC, April 09, 2024 (GLOBE NEWSWIRE) -- Food & Society at the Aspen Institute has released its 2024 Food is Medicine Research Action Plan.

Key Points: 
  • Washington, DC, April 09, 2024 (GLOBE NEWSWIRE) -- Food & Society at the Aspen Institute has released its 2024 Food is Medicine Research Action Plan.
  • It is the first report to pull together the latest peer-reviewed Food is Medicine research in a digestible, comprehensible, and action-oriented format.
  • Associated health outcomes like diabetes and heart disease remain far greater among Black and Latinx individuals and households.
  • Like the original, the revised version of the Research Action Plan has been made possible thanks to the continuing support of the Walmart Foundation.

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Retrieved on: 
Tuesday, April 9, 2024
Research, CARE, OSA, Health, Sleep apnea, Conditional sentence, Obstructive sleep apnea, Risk, Diabetes, DDS, Patient, Stroke, Sleep, Chronic pain, Quality of life, Heart failure, Therapy, FDA, CMS, Dementia, Pharmaceutical industry

Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

Key Points: 
  • Effective immediately, this milestone achievement allows millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.
  • “Prior to these latest developments, moderate to severe OSA patients on Medicare were relegated almost entirely to a lifetime of some form of CPAP—something most patients find undesirable.
  • Our CARE oral medical devices, on the other hand, can significantly improve and even resolve OSA in about 12 months, with no further intervention required in most cases,” said Kirk Huntsman, Vivos Chairman and Chief Executive Officer.
  • “We are very pleased the Centers for Medicare and Medicaid Services (CMS) recognizes and validates the benefits our FDA cleared devices can have on the lives of patients diagnosed with OSA.

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Retrieved on: 
Tuesday, April 9, 2024
Quality of life, Senior, Eye, Employment, Compensated emancipation, Diabetic retinopathy

BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu.

Key Points: 
  • BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu.
  • The awards were approved by the Compensation Committee of Ocular and were made as inducements material to Dr. Zhu’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock unit award is scheduled to vest over three years, in equal annual installments, beginning on Dr. Zhu’s employment commencement date and subject to her continued service to Ocular through the applicable vesting dates.
  • The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

Retrieved on: 
Monday, April 8, 2024
Blood pressure, Exercise, MRCP, Patient, Heart rate, Heart, Journal, Aes, Medical Center, Quality of life, Efficacy, Heart failure, American College, HCM, Clinical trial, CPET, ACC, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today announced that results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat in patients with symptomatic nHCM, were presented in a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • “We are pleased with the IMPROVE-HCM clinical trial results presented today at ACC and simultaneously published in JACC, confirming the importance of these results for patients living with nHCM,” said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals.
  • “Based on these positive results, we plan to initiate the Phase 3 FORTITUDE-HCM clinical trial in patients with symptomatic nHCM later this year.
  • Most treatment emergent adverse events (AEs) were self-limiting and mild to moderate in severity occurring in 24 ninerafaxstat treated patients (70.6%) vs. 20 patients on placebo (60.6%).
  • improved) from 31.2 to 30.9 in the ninerafaxstat treated group and worsened from 32.7 to 34.3 in the placebo group.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA

Retrieved on: 
Monday, April 8, 2024
Arthralgia, Osteoarthritis, DVM, Mayra Andrade, Hip, Patient, Synovial joint, Pain management, ACVS, Limp, Quality of life, Trial of the century, Dog, JW Marriott Hotels, JW Marriott Indianapolis, Joint, Pain, CCRT, VOS, Animal, CCD, Poultry farming

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
    Pain Management Forum Exhibit Details:
    Location: The JW Marriott in Indianapolis, Indiana
    Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Retrieved on: 
Monday, April 8, 2024
Diagnosis, The Lancet, Depression, NASW, Partnership, PAP, Psychotherapy, Palliative care, Patient, Research, Gold, American Psychological Association, Standard of care, Anxiety, Cancer, Doctor of Philosophy, Quality of life, Adjustment disorder, Social work, World Health Organization, Clinical trial, Safety, Adjustment, WHO, National Association, DSM-IV codes, APA, FDA, Physician, Health, PBM, Practitioner, Nursing

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian subsidiary, Psyence Australia Pty Ltd. (“Psyence Australia”), has entered into a partnership with Fluence , a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial.
  • According to Lancet Oncology, Adjustment Disorder affects as many as 19% of patients following a life-limiting cancer diagnosis.
  • “The success of the clinical trial relies on rigorous, standardized therapist training designed to achieve the highest standard of patient care,” said Elizabeth Nielson, PhD, Fluence co-founder.
  • Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.

Bestqool Launches Innovative Red Light Therapy Devices for Eczema Relief

Retrieved on: 
Friday, April 5, 2024
Skin care, Fibroblast, Health, Certification, RLT, Psoriasis, Adenosine triphosphate, Cell, Serotonin, Patient, Photobiology, Tissue, Rosacea, Mitochondrion, Mental health, History, Red, Quality of life, Dermatitis, Itch, Keratinocyte, Acne, Skin, Pollution, Erythema, Cytokine, Irritation, ATP, Immune system, Recurrence, Fatigue, Swelling, FDA, Waste, Medical device

Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.

Key Points: 
  • Bestqool's advanced red light therapy offers a non-invasive, natural solution for managing this pervasive skin issue.
  • Combining red light therapy with topical ointments can be a complementary approach for effective eczema treatment.
  • Bestqool's latest range of portable red light therapy devices are designed to be both convenient and effective for home use.
  • Adding red light therapy to daily care and prevention can repair both inside and outside by lowering eczema recurrence and improving the quality of life.

FuelPositive Welcomes Deputy Minister of Agriculture and Agri-Food Canada to Facility in Waterloo and Announces Non-Brokered Private Placement

Retrieved on: 
Thursday, April 4, 2024
Sustainability, Climate change, Government, Farmer, TSX Venture Exchange, Debt, Offering, University, Biophysical environment, GHG, Chairperson, Research, Mental health, Policy, Anxiety, Ontario Agricultural College, Rural development, Quality of life, Central Statistics Office (India), EEStor, RPP, Fertilizer, Suicide, MCIP, Animal, Federal, School, Agriculture

"Deputy Minister Beck recently visited our team at our new facility during her visit to the Kitchener-Waterloo region.

Key Points: 
  • "Deputy Minister Beck recently visited our team at our new facility during her visit to the Kitchener-Waterloo region.
  • Deputy Minister Beck was joined by Alec Nicholls, Director General, Agriculture and Agri-Food Canada, Melissa Reginato, Senior Markets and Trade, Agriculture and Agri-Food Canada and Hadley Carpenter, Regional Director, Agriculture and Agri-Food Canada, who was instrumental in organizing the visit.
  • Our technology embodies the spirit of progress and collaboration and showcases Canada's leadership in pioneering solutions that address pressing global challenges.
  • The governmental visit was a valuable opportunity for the FuelPositive team to engage in meaningful discussions with Deputy Minister Beck.